Qiagen N.V.
QIA | F
Overview
Corporate Details
- ISIN(s):
- DE000A286LP0 (+4 more)
- LEI:
- 54930036WK3GMCN17Z57
- Country:
- Netherlands (Kingdom of the)
- Address:
- HULSTERWEG 82, 5912 PL VENLO
- Website:
- https://www.qiagen.com/
- Sector:
- Human health and social work activities
- Industry:
- Hospital activities
Description
QIAGEN serves more than 500,000 customers around the globe, all seeking answers from the building blocks of life – DNA, RNA and proteins. We deliver Sample to Insight solutions for molecular testing, propelling our customers from start to finish to unlock new insights. This is how we make improvements in life possible. Our product portfolio supports our customers across the continuum of molecular testing in molecular diagnostics and life sciences. From the first important step of DNA, RNA and protein extraction from biological samples, to novel testing technologies targeting single or multiple molecular variants, and software to analyze and interpret molecular data to deliver valuable insights. Our automation systems bring together all of these steps in seamless end-to-end workflows.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Qiagen N.V..
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-05-13 00:00 |
Foreign Filer Report
Q1 statement / Q1 financial report 2025
|
English | 693.8 KB | |
| 2025-05-07 14:35 |
Notice of Dividend Amount
QIAGEN N.V.: QIAGEN to propose initiation of annual cash dividend for sharehold…
|
English | 6.8 KB | |
| 2025-04-28 16:33 |
Annual Report (ESEF)
Qiagen N.V., Jaarlijkse financiële verslaggeving
|
English | 23.4 MB | |
| 2025-04-06 18:20 |
Earnings Release
QIAGEN N.V.: QIAGEN announces strong preliminary Q1 2025 results and updates fu…
|
English | 7.2 KB | |
| 2025-03-31 00:00 |
Annual Report
Annual financial report 2024
|
English | 6.2 MB | |
| 2025-02-06 06:31 |
Earnings Release
QIAGEN delivers solid Q4 2024 growth ahead of outlook
|
English | 478.9 KB | |
| 2025-01-13 18:55 |
Transaction in Own Shares
QIAGEN N.V.: QIAGEN to return approximately $300 million to shareholders throug…
|
English | 7.7 KB | |
| 2025-01-12 18:55 |
Share Issue/Capital Change
QIAGEN N.V.: QIAGEN to return approximately $300 million to shareholders throug…
|
English | 7.7 KB | |
| 2024-11-07 07:30 |
Earnings Release
QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024…
|
English | 421.6 KB | |
| 2024-09-03 09:01 |
Capital/Financing Update
QIAGEN N.V. launches non-US offering of net share settled convertible bonds
|
English | 56.8 KB | |
| 2024-09-03 09:01 |
Capital/Financing Update
QIAGEN N.V. launches non-US offering of net share settled convertible bonds
|
English | 44.5 KB | |
| 2024-08-16 15:34 |
Interim Report
|
English | 565.7 KB | |
| 2024-08-01 07:13 |
Earnings Release
QIAGEN delivers solid performance and exceeds outlook for Q2 2024
|
English | 463.7 KB | |
| 2024-04-30 07:33 |
Earnings Release
QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-y…
|
English | 384.1 KB | |
| 2024-04-26 18:20 |
Annual Report (ESEF)
|
English | 10.4 MB |
Automate Your Workflow. Get a real-time feed of all Qiagen N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Qiagen N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-04-17 | S. Rusckowski | Non-Executive member | Other | 26 | N/A |
| 2023-03-14 | E.R. Mardis | Non-Executive member | Sell | 4,739 | 218,422.41 USD |
| 2023-02-28 | E. Pisa | Non-Executive member | Other | 7,917 | N/A |
| 2023-02-21 | R. Sackers | Non-Executive member | Other | 51,500 | N/A |
| 2022-12-01 | R. Sackers | Non-Executive member | Sell | 30,000 | 1,500,000.00 USD |
| 2022-10-31 | M. Colpan | Non-Executive member | Other | 457 | N/A |
| 2022-06-08 | R. Sackers | Non-Executive member | Sell | 32,398 | 1,522,706.00 USD |
| 2022-03-31 | R. Sackers | Non-Executive member | Other | 72,944 | N/A |
| 2022-03-15 | R. Sackers | Non-Executive member | Other | 7,606 | N/A |
| 2022-03-14 | E.R. Mardis | Non-Executive member | Sell | 5,003 | 228,330.77 USD |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
MLP SAĞLIK HİZMETLERİ A.Ş. | Türkiye | MPARK | |
|
Nordhealth AS | Norway | NORDH | |
|
Omda AS | Norway | CSAM | |
|
One Health Group Plc | United Kingdom | OHG | |
|
OPTIBIOTIX HEALTH PLC | United Kingdom | OPTI | |
|
OPTIMA HEALTH PLC | United Kingdom | OPT | |
|
ORPEA | France | ORP | |
|
Pihlajalinna Oyj | Finland | PIHLIS | |
|
Ramsay Générale de Santé | France | GDS | |
|
Remedis Spolka Akcyjna W Upadlosci | Poland | REM |